Ginkgo Bioworks Holdings, Inc.
DNA
$9.34
-$0.56-5.66%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -80.76M | -60.30M | -90.96M | -107.53M | -56.40M |
| Total Depreciation and Amortization | 168.00K | 15.79M | 15.37M | 15.65M | 3.87M |
| Total Amortization of Deferred Charges | 14.00M | -- | -- | -- | 13.30M |
| Total Other Non-Cash Items | 21.20M | 26.97M | 35.64M | 47.27M | 33.77M |
| Change in Net Operating Assets | 13.78M | -22.71M | -11.57M | 2.18M | -98.04M |
| Cash from Operations | -31.61M | -40.25M | -51.52M | -42.44M | -103.50M |
| Capital Expenditure | 0.00 | -38.00K | -7.62M | -13.71M | -15.09M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 57.00K | 591.00K |
| Cash Acquisitions | -- | -- | -- | 0.00 | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -72.82M | -63.85M | -191.06M | 568.00K | 4.30M |
| Cash from Investing | -72.82M | -63.89M | -198.68M | -13.09M | -10.20M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -24.00K | -98.00K | -207.00K | -203.00K | -200.00K |
| Issuance of Common Stock | 10.32M | -- | -- | 0.00 | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -355.00K | -- | -- | 0.00 | -265.00K |
| Cash from Financing | 9.94M | -98.00K | -207.00K | -203.00K | -465.00K |
| Foreign Exchange rate Adjustments | 93.00K | 186.00K | 74.00K | -73.00K | -35.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -94.39M | -104.05M | -250.34M | -55.80M | -114.20M |